The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York September 17, 2020. — Reuters pic
REGEN-COV — featuring potent neutralizing antibodies called imdevimab and casirivimab — remained effective against both variants, the company said in a statement, although casirivimab’s potency against the South African variant was “reduced.” “These data show the continued ability of REGEN-COV to neutralize emerging strains, further validating our multi-antibody cocktail approach to infectious diseases,” said George Yancopoulos, Regeneron’s president and chief scientific officer.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: